Shanghai Pharmaceuticals Holding Revenue

Shanghai Pharmaceuticals Holding had revenue of 70.22B CNY in the quarter ending September 30, 2024, with 8.16% growth. This brings the company's revenue in the last twelve months to 272.42B, up 6.88% year-over-year. In the year 2023, Shanghai Pharmaceuticals Holding had annual revenue of 260.30B with 12.21% growth.

Revenue (ttm)

272.42B CNY

Revenue Growth

+6.88%

P/S Ratio

n/a

Revenue / Employee

5.66M CNY

Employees

48,164

Market Cap

71.79B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	186.57B	27.48B	17.27%
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro
Dec 31, 2014	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
BeiGene	26.04B
Hansoh Pharmaceutical Group Company	13.00B
JD Health International	58.84B
WuXi Biologics	18.39B
Sinopharm Group	634.32B
Alibaba Health Information Technology	31.39B
Akeso	2.01B
Innovent Biologics	8.01B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

4 weeks ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
4 weeks ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News